SCHEMBL14490221

SCHEMBL14490221

Cc1cc(S(=O)(=O)N2CCCN(C(=O)OC(C)(C)C)CC2)ccc1Br

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.55
RIN1 Q13671 1/20 0.55
TGM2 P21980 10/20 0.52
F13A1 P00488 7/20 0.52
TGM1 P22735 4/20 0.52
ALDH1A1 P00352 3/20 0.51
PKM P14618 1/20 0.51
LMNA P02545 2/20 0.50
HTT P42858 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
TSHR P16473 1/20 0.46
HSD17B10 Q99714 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
MAPT P10636 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2376710 0.96 ABL1 (0.59) ABL1RIN1TGM2F13A1TGM1
SCHEMBL14490217 0.88 TGM2 (0.53) TGM2F13A1TGM1PKMSMN1; SMN2
SCHEMBL14490210 0.85 TGM2 (0.59) TGM2F13A1TGM1ALDH1A1PKM
SCHEMBL5738205 0.84 TGM2 (0.55) TGM2F13A1TGM1ALDH1A1LMNA
SCHEMBL1955697 0.84 ALDH1A1 (0.62) TGM2F13A1TGM1ALDH1A1PKM
SCHEMBL5443780 0.84 ABL1 (0.61) ABL1RIN1ALDH1A1PKMLMNA
SCHEMBL29596865 0.83 TGM2 (0.50) TGM2F13A1TGM1MEN1KMT2A
SCHEMBL2378926 0.83 TGM2 (0.56) TGM2F13A1TGM1PKMSMN1; SMN2
SCHEMBL31165481 0.83 TGM2 (0.56) TGM2F13A1TGM1PKMSMN1; SMN2
SCHEMBL6977995 0.82 TGM2 (0.58) TGM2F13A1TGM1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070149508-A1 Six membered heteroaromatic inhibitors targeting resistant kinase mutations TARGEGEN, INC. (US) 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149508-A1 Six membered heteroaromatic inhibitors targeting resistant kinase mutations ABL1, KDR, BCR ABL1 1/4885RIN1 2786/4885TGM2 1975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.